Unknown

Dataset Information

0

Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.


ABSTRACT: Mucopolysaccharidosis type I (MPS-I) is a severe genetic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) enzyme. Ex vivo hematopoietic stem cell (HSC) gene therapy is a promising therapeutic approach for MPS-I, as demonstrated by preclinical studies performed in naive MPS-I mice. However, after enzyme replacement therapy (ERT), several MPS-I patients develop anti-IDUA immunity that may jeopardize ex vivo gene therapy efficacy. Here we treat MPS-I mice with an artificial immunization protocol to mimic the ERT effect in patients, and we demonstrate that IDUA-corrected HSC engraftment is impaired in pre-immunized animals by IDUA-specific CD8+ T cells spared by pre-transplant irradiation. Conversely, humoral anti-IDUA immunity does not impact on IDUA-corrected HSC engraftment. The inclusion of lympho-depleting agents in pre-transplant conditioning of pre-immunized hosts allowes rescue of IDUA-corrected HSC engraftment, which is proportional to CD8+ T cell eradication. Overall, these data demonstrate the relevance of pre-existing anti-transgene T cell immunity on ex vivo HSC gene therapy, and they suggest the application of tailored immune-depleting treatments, as well as a deeper immunological characterization of patients, to safeguard the therapeutic effects of ex vivo HSC gene therapy in immunocompetent hosts.

SUBMITTER: Squeri G 

PROVIDER: S-EPMC6612662 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.

Squeri Giorgia G   Passerini Laura L   Ferro Francesca F   Laudisa Cecilia C   Tomasoni Daniela D   Deodato Federica F   Donati Maria Alice MA   Gasperini Serena S   Aiuti Alessandro A   Bernardo Maria Ester ME   Gentner Bernhard B   Naldini Luigi L   Annoni Andrea A   Biffi Alessandra A   Gregori Silvia S  

Molecular therapy : the journal of the American Society of Gene Therapy 20190419 7


Mucopolysaccharidosis type I (MPS-I) is a severe genetic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) enzyme. Ex vivo hematopoietic stem cell (HSC) gene therapy is a promising therapeutic approach for MPS-I, as demonstrated by preclinical studies performed in naive MPS-I mice. However, after enzyme replacement therapy (ERT), several MPS-I patients develop anti-IDUA immunity that may jeopardize ex vivo gene therapy efficacy. Here we treat MPS-I mice with an artificial immuniza  ...[more]

Similar Datasets

| S-EPMC5363314 | biostudies-literature
| S-EPMC3581049 | biostudies-literature
| S-EPMC3732124 | biostudies-literature
| S-EPMC3840485 | biostudies-literature
| S-EPMC5098439 | biostudies-literature
2020-07-02 | GSE147091 | GEO
| S-EPMC5746592 | biostudies-literature
2024-10-10 | GSE276902 | GEO
2024-10-10 | GSE276904 | GEO
| S-EPMC7414147 | biostudies-literature